

MOLECULAR INTELLIGENCE™

Evidence-Guided Tumour Profiling Services



Tumour Profiling Menu

Molecular Intelligence™ Service, from Caris Life Sciences® is designed to help the physician to build an individualised treatment plan for each patient. Our service integrates sophisticated tumour analyses with evidence on drug / biomarker associations that are established by continuous and extensive literature review and assessment.

SERVICE OFFERINGS:

Comprehensive Plus

Reports a broad range of therapeutic associations. Includes expanded mutational analysis reporting for up to 44 genes by Next-Generation Sequencing.

Comprehensive

Reports a broad range of therapeutic associations. Includes only those sequencing biomarkers associated in our database with clinical evidence.

Single Test Orders

All of our biomarker tests, including the next generation sequencing, 44 gene pan tumour panel, may be ordered individually.

This profile menu details the biomarkers and associated therapies analysed by tumour type. The definitive list of assays included in each profile can be found online at www.carislifesciences.eu.

Next-Generation Sequencing Biomarkers

Next-Generation Sequencing (NGS) provides the ability to rapidly examine and more broadly detect somatic mutations across hundreds of hotspots in cancer genomes, through a highly multiplexed, comprehensive assay.

ABL1	BRAF	ERBB2	FLT3	IDH1	KRAS	NPM1	PTPN11	SMO
AKT1	CDH1	ERBB4	GNA11	JAK2	MET	NRAS	RB1	STK11
ALK	CSF1R	FBXW7	GNAS	JAK3	MLH1	PDGFRA	RET	TP53
APC	CTNNB1	FGFR1	HNF1A	KDR (VEGFR2)	MPL	PIK3CA	SMAD4	VHL
ATM	EGFR	FGFR2	HRAS	KIT	NOTCH1	PTEN	SMARCB1	

To order Caris Molecular Intelligence Services or to speak with a Caris Life Sciences' representative, call

+41 21 533 53 00 / +800 12 12 30 30

or email to EUCustomerServices@carisls.com,
or visit us online at www.carislifesciences.eu.



Breast Carcinoma

Agent	Biomarker	Platform
fulvestrant, tamoxifen, toremifene, anastrozole, exemestane, letrozole, leuprolide, goserelin, megestrol acetate	ER	IHC
	PR	IHC
trastuzumab	HER2	IHC, FISH/CISH
	PTEN	IHC
	PIK3CA	NextGen Seq
lapatinib, pertuzumab	HER2	IHC, FISH/CISH
doxorubicin, liposomal-doxorubicin, epirubicin	TOP2A	FISH/CISH
	HER2	FISH/CISH
fluorouracil, capecitabine, pemetrexed	TS	IHC
docetaxel, paclitaxel	TLE3	IHC
	Pgp	IHC
gemcitabine	RRM1	IHC
irinotecan	TOPO1	IHC
imatinib	cKIT	NextGen Seq
	PDGFRA	NextGen Seq
sunitinib	cKIT	NextGen Seq
nab-paclitaxel	SPARCm	IHC
	SPARcp	IHC
temozolomide, dacarbazine	MGMT	IHC
vemurafenib	BRAF	NextGen Seq
protein expression status	AR	IHC
	TUBB3	IHC
mutational status	IDH1	NextGen Seq
everolimus, temsirolimus, clinical trials	PIK3CA	NextGen Seq
	PTEN	IHC
	BRAF	NextGen Seq
	KRAS	NextGen Seq
clinical trials (MEK and BRAF inhibitors)	BRAF	NextGen Seq
	KRAS	NextGen Seq
	NRAS	NextGen Seq
clinical trials (angiogenesis inhibitors)	VHL	NextGen Seq
clinical trials (PIK3CA, mTOR, MEK, angiogenesis, and IGF pathway inhibitors)	PTEN	NextGen Seq
clinical trials (cMET inhibitors)	cMET	IHC, FISH/CISH

NSCLC

Agent	Biomarker	Platform
erlotinib, gefitinib	EGFR	NextGen Seq
	KRAS	NextGen Seq
	cMET	IHC, FISH/CISH
	PIK3CA	NextGen Seq
	PTEN	IHC
crizotinib	ALK	FISH
	ROS1	FISH
pemetrexed, fluorouracil, capecitabine	TS	IHC
gemcitabine	RRM1	IHC
docetaxel, paclitaxel	TLE3	IHC
	TUBB3	IHC
	Pgp	IHC
cetuximab	EGFR	IHC (H-Score)
vemurafenib	BRAF	NextGen Seq
imatinib	cKIT	NextGen Seq
	PDGFRA	NextGen Seq
sunitinib	cKIT	NextGen Seq
doxorubicin, liposomal-doxorubicin, epirubicin	TOP2A	FISH/CISH
	HER2	FISH/CISH
irinotecan	TOPO1	IHC
temozolomide, dacarbazine	MGMT	IHC
nab-paclitaxel	SPARCm	IHC
	SPARcp	IHC
mutational status	IDH1	NextGen Seq
protein expression status	AR	IHC
	ER	IHC
	PR	IHC
clinical trials (MEK and BRAF inhibitors)	BRAF	NextGen Seq
	KRAS	NextGen Seq
	NRAS	NextGen Seq
clinical trials (pan-HER), trastuzumab, lapatinib	HER2	IHC, FISH/CISH
clinical trials (everolimus and temsirolimus)	PIK3CA	NextGen Seq
	PTEN	IHC
clinical trials (angiogenesis inhibitors)	VHL	NextGen Seq
clinical trials (PIK3CA, mTOR, MEK, angiogenesis, and IGF pathway inhibitors)	PTEN	NextGen Seq

Ovarian Carcinoma

Agent	Biomarker	Platform
docetaxel, paclitaxel	TUBB3	IHC
	Pgp	IHC
irinotecan, topotecan	TOPO1	IHC
gemcitabine	RRM1	IHC
doxorubicin, liposomal-doxorubicin, epirubicin	TOP2A	FISH/CISH
	HER2	FISH/CISH
fulvestrant, tamoxifen, letrozole, anastrozole	ER	IHC
megestrol acetate, leuprolide	ER	IHC
	PR	IHC
pemetrexed, capecitabine, fluorouracil	TS	IHC
trastuzumab	HER2	IHC, FISH/CISH
vemurafenib	BRAF	NextGen Seq
imatinib	cKIT	NextGen Seq
	PDGFRA	NextGen Seq
sunitinib	cKIT	NextGen Seq
temozolomide, dacarbazine	MGMT	IHC
nab-paclitaxel	SPARCm	IHC
	SPARCp	IHC
protein expression status	AR	IHC
	TLE3	IHC
mutational status	IDH1	NextGen Seq
	PIK3CA	NextGen Seq
everolimus, temsirolimus, clinical trials	PTEN	IHC
	cMET	IHC, FISH/CISH
clinical trials (angiogenesis inhibitors)	VHL	NextGen Seq
clinical trials (PIK3CA, mTOR, MEK, angiogenesis, and IGF pathway inhibitors)	PTEN	NextGen Seq
clinical trials (MEK and BRAF inhibitors)	KRAS	NextGen Seq
	BRAF	NextGen Seq
	NRAS	NextGen Seq

Colorectal Carcinoma

Agent	Biomarker	Platform
cetuximab, panitumumab	KRAS	NextGen Seq
	BRAF	NextGen Seq
	NRAS	NextGen Seq
	PIK3CA	NextGen Seq
	PTEN	IHC
fluorouracil, capecitabine, pemetrexed	TS	IHC
irinotecan	TOPO1	IHC
imatinib	cKIT	NextGen Seq
	PDGFRA	NextGen Seq
sunitinib	cKIT	NextGen Seq
doxorubicin, liposomal-doxorubicin, epirubicin	HER2	FISH/CISH
	TOP2A	FISH/CISH
trastuzumab, lapatinib	HER2	IHC, FISH/CISH
gemcitabine	RRM1	IHC
temozolomide, dacarbazine	MGMT	IHC
nab-paclitaxel	SPARCm	IHC
	SPARCp	IHC
docetaxel, paclitaxel	TLE3	IHC
	TUBB3	IHC
	Pgp	IHC
mutational status	IDH1	NextGen Seq
protein expression status	AR	IHC
	ER	IHC
	PR	IHC
everolimus, temsirolimus, clinical trials	PIK3CA	NextGen Seq
	PTEN	IHC
	KRAS	NextGen Seq
	BRAF	NextGen Seq
clinical trials (angiogenesis inhibitors)	VHL	NextGen Seq
clinical trials (PIK3CA, mTOR, MEK, angiogenesis, and IGF pathway inhibitors)	PTEN	NextGen Seq
clinical trials (cMET inhibitors)	cMET	IHC, FISH/CISH

Melanoma

Agent	Biomarker	Platform
vemurafenib	BRAF	PCR (cobas [®])
temozolomide, dacarbazine	MGMT	IHC
imatinib	cKIT	NextGen Seq
	PDGFRA	NextGen Seq
sunitinib	cKIT	NextGen Seq
nab-paclitaxel	SPARCM	IHC
	SPARCP	IHC
paclitaxel, docetaxel	TLE3	IHC
	TUBB3	IHC
	Pgp	IHC
doxorubicin, liposomal-doxorubicin, epirubicin	HER2	FISH/CISH
	TOP2A	FISH/CISH
trastuzumab, lapatinib	HER2	IHC, FISH/CISH
gemcitabine	RRM1	IHC
irinotecan	TOPO1	IHC
fluorouracil, capecitabine, pemetrexed	TS	IHC
mutational status	IDH1	NextGen Seq
protein expression status	AR	IHC
	ER	IHC
	PR	IHC
everolimus, temsirolimus, clinical trials	PIK3CA	NextGen Seq
	PTEN	IHC
clinical trials (HDAC, MEK inhibitors) for Uveal Melanoma	GNA11 <small>(Uveal Melanoma only)</small>	NextGen Seq
clinical trials (angiogenesis inhibitors)	VHL	NextGen Seq
clinical trials (PIK3CA, mTOR, MEK, angiogenesis, and IGF pathway inhibitors)	PTEN	NextGen Seq
clinical trials (cMET inhibitors)	cMET	IHC, FISH/CISH
clinical trials (MEK and BRAF inhibitors)	BRAF	NextGen Seq
	KRAS	NextGen Seq
	NRAS	NextGen Seq

All Other Solid Tumours

Agent	Biomarker	Platform
docetaxel, paclitaxel	TLE3	IHC
	TUBB3	IHC
	Pgp	IHC
capecitabine, fluorouracil, pemetrexed	TS	IHC
doxorubicin, liposomal-doxorubicin, epirubicin	HER2	FISH/CISH
	TOP2A	FISH/CISH
irinotecan, topotecan	TOPO1	IHC
gemcitabine	RRM1	IHC
temozolomide, dacarbazine	MGMT	IHC <small>(excluding glioma)</small>
	MGMT-Me	Pyrosequencing <small>(glioma ONLY)</small>
	IDH1*	NextGen Seq
nab-paclitaxel	SPARCM	IHC
	SPARCP	IHC
abiraterone, bicalutamide, flutamide	AR	IHC
fulvestrant, tamoxifen, toremifene, anastrozole, exemestane, letrozole, megestrol acetate, leuprolide, goserelin	ER	IHC
	PR	IHC
trastuzumab, lapatinib	HER2	IHC, FISH/CISH
imatinib	cKIT	NextGen Seq
	PDGFRA	NextGen Seq
sunitinib, sorafenib (GIST only)	cKIT	NextGen Seq
vemurafenib	BRAF	NextGen Seq
everolimus, temsirolimus, clinical trials	PIK3CA	NextGen Seq
	PTEN	IHC
clinical trials (cMET inhibitors)	cMET	IHC, FISH/CISH
clinical trials (MEK and BRAF inhibitors)	BRAF	NextGen Seq
	KRAS	NextGen Seq
	NRAS	NextGen Seq
clinical trials (angiogenesis inhibitors)	VHL	NextGen Seq
clinical trials (PIK3CA, mTOR, MEK, angiogenesis, and IGF pathway inhibitors)	PTEN	NextGen Seq

* IDH1 will only associate with temozolomide and decarbazine for High Grade Gliomas

To order Caris Molecular Intelligence Services or to speak with a Caris Life Sciences' representative, call
+41 21 533 53 00 / +800 12 12 30 30
 or email to EUCustomerServices@carisls.com,
 or visit us online at www.carislifesciences.eu.

